Mumbai: Procter & Gamble Health Limited (formerly Merck Limited) announced today its financial results for the quarter ended March 31, 2018. The company has recorded a total revenue of ₹249 crores, up 22.2% vs. year ago (Sales from operations up by 17%) driven by a strong performance across brands, growth in exports, higher interest income and improved execution.
The Profit After Tax (PAT) was ₹40.7 crores Vs ₹22.7 crores from continued operations, up versus year ago driven by high interest income and operational efficiencies.
Milind Thatte, Managing Director, Procter & Gamble Health Limited said, “We have continued our solid growth trajectory, recording a robust 17% growth in this quarter. With a brand portfolio backed by science and trusted by doctors, pharmacists and consumers, and the best of Consumer Health capabilities and cultures, we are working towards creating a much stronger presence in India’s fast-growing Consumer Health industry.”